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Abstract 1 
Background: Variation in induced models of autoimmunity has been attributed to the 2 
housing environment and its effect on the gut microbiota. In Graves’ disease (GD), 3 
autoantibodies to the thyrotropin receptor (TSHR) cause autoimmune hyperthyroidism. Many 4 
GD patients develop Graves’ orbitopathy (GO) characterized by orbital tissue remodeling 5 
including adipogenesis. Murine models of GD/GO would help delineate pathogenetic 6 
mechanisms and although several have been reported most lack reproducibility. A model 7 
comprising immunization of female BALBc mice with a TSHR expression plasmid using in 8 
vivo electroporation, was reproduced in two independent laboratories. Similar orbital disease 9 
was induced in both centers, but differences were apparent (e.g. hyperthyroidism in Center 1 10 
but not Center 2).  We hypothesized a role for the gut microbiota influencing the outcome 11 
and reproducibility of induced GO. 12 
Results: We combined metataxonomics (16S rRNA gene sequencing) and traditional 13 
microbial culture of the intestinal contents from the GO murine model, to analyze the gut 14 
microbiota in the two centers. We observed significant differences in alpha, beta-diversity 15 
and in the taxonomic profiles, e.g. Operational Taxonomic Units (OTUs) from the genus 16 
Lactobacillus were more abundant in Center 2, Bacteroides and Bifidobacterium counts were 17 
more abundant in Center 1 where we also observed a negative correlation between the OTUs 18 
of the genus Intestinimonas and TSHR autoantibodies. Traditional microbiology largely 19 
confirmed the metataxonomics data and indicated significantly higher yeast counts in Center 20 
1 TSHR-immunized mice. We also compared the gut microbiota between immunization 21 
groups within the Center 2, comprising the TSHR or βgal control immunized mice and naïve 22 
untreated mice. We observed a shift of the TSHR immunized mice bacterial communities 23 
described by the beta-diversity weighted Unifrac. Furthermore, we observed a significant 24 
 2 
positive correlation between the presence of Firmicutes and orbital-adipogenesis specifically 25 
in TSHR-immunized mice. 26 
Conclusions: The significant differences observed in microbiota composition from BALBc 27 
mice undergoing the same immunization protocol in comparable specific-pathogen free (SPF) 28 
units in different centers support a role for the gut microbiota in modulating the induced 29 
response. The gut microbiota might also contribute to the heterogeneity of induced response 30 
since we report potential disease-associated microbial taxonomies and correlation with ocular 31 
disease. 32 
 33 
Keywords: Graves’ orbitopathy; Graves’ disease; Induced animal model; Gut microbiota; 34 
TSHR; Metataxonomics; Orbital adipogenesis; Firmicutes. 35 
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Background 36 
The poor reproducibility of murine models of human diseases has become a puzzling 37 
phenomenon in recent decades. Apart from the genetic background of the strains used, the 38 
type of animal housing, diet and even the vendor can influence disease phenotype [1,2]. 39 
In Graves’ disease (GD) and Graves’ Orbitopathy (GO), in vivo models could help to unravel 40 
the pathogenetic mechanisms leading to autoimmunity and identify new therapeutic targets. 41 
[3]. The lack of spontaneous models of GD and GO necessitates induction of disease under 42 
laboratory conditions (reviewed in [4]). 43 
Graves’ disease is an organ-specific antibody-mediated autoimmune disease, governed by 44 
both genetic predisposition and environmental factors, in which thyroid-stimulating 45 
antibodies (TSAb) mimic the function of thyroid-stimulating hormone (TSH) to activate the 46 
thyrotropin receptor (TSHR). Moreover, the presence of thyroid-stimulating blocking 47 
antibodies (TSBAb), which inhibit the TSHR signaling cascade, and neutral antibodies to 48 
TSHR have been described in GD [5]. GD symptoms include hyperthyroidism, weight loss, 49 
heat intolerance and tremors; it affects about 2% of the population in the UK, with a female 50 
predominance. About 20% of GD patients develop an eye disease, Graves’ orbitopathy or 51 
ophthalmopathy (GO), characterized by pro-inflammatory cells and tissue remodeling 52 
(extraocular muscle inflammation, adipogenesis, over-production of extra-cellular matrix) in 53 
the orbit [6]. 54 
Several GD mouse models have been developed using different immunization protocols with 55 
no signs of concomitant eye disease as previously reviewed [4,7-8]. Ludgate and colleagues 56 
established a TSHR-induced GO model by genetic immunization; i.e. injecting a TSHR 57 
expression plasmid [9]. Mice developed thyroiditis plus some aspects of GO and disease 58 
could be transferred to naive recipients using the TSHR-primed T cells from the genetically 59 
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immunized mice. However, the model could not be reproduced in a different animal unit 60 
(neither was specific-pathogen free (SPF)) and the TSHR-induced disease was quite distinct 61 
from that previously described, which the authors postulated might be due to microorganisms 62 
[10]. It has also been reported that TSHR-immunized mice from a conventional environment 63 
had higher and more persistent TSAb levels than mice in SPF units [11]. 64 
Recently, Berchner-Pfannschmidt and colleagues reported the induction of GO-like disease in 65 
two independent SPF units [12]. The immunization protocol utilized genetic delivery of 66 
TSHR A-subunit plasmid by close field electroporation, which leads to features of GD 67 
accompanied by symptoms of eye disease, such as adipogenesis and inflammatory infiltrates 68 
in the orbit [7,13]. Controls received a plasmid encoding the β-galactosidase (βgal) gene 69 
delivered by the same procedure. Most aspects of the model were reproduced successfully, 70 
however, there was heterogeneity in induced disease and differences in thyroid function in 71 
the animals undergoing experimental GO in the two locations [12]. 72 
Over the years the gut microbiota has been associated with several diseases [14-17] and its 73 
confounding role in establishing or reproducing disease phenotype in murine models has also 74 
been proposed [18].  75 
The murine model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), 76 
seems to be highly influenced by the gut microbiota. Oral antibiotic immunization and 77 
consequent depletion of the gut bacteria, before disease induction, resulted in protection from 78 
disease development, along with reduction in pro-inflammatory mediators such as IL-17 and 79 
an increased Th2-immune response [19]. On the contrary, the intestinal monocolonization of 80 
germ free mice (sterile) with segmented filamentous bacteria (SFB) restored the disease 81 
phenotype, along with an increased number of Th17 cells in the CNS, suggesting a direct 82 
interplay of the gut microbiota and the immune response in EAE development [20].  83 
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Based on these observations, we hypothesized that the gut microbiota itself might play a 84 
major role not only in the establishment, but also in the reproducibility of the GO animal 85 
model described above. The presence or absence not only of pathogens, but also of symbiotic 86 
and commensal bacteria can favor an immune response more prone to inflammation and 87 
conducive to autoimmunity [21].  88 
We aimed to characterize, for the first time, the gut microbiota of the GD/GO models via a 89 
combination of metataxonomics (16S rRNA gene sequencing) and traditional microbial 90 
culture approaches. We compared the gut contents of TSHR immunized mice from the two 91 
centers to understand whether variation in gut composition could explain differences in the 92 
disease induced. Within one center, we then characterized the gut microbiota between 93 
different immunizations (TSHR and βgal) and compared them with untreated mice, to 94 
determine whether the gut microbiota can influence the outcome and correlate with disease 95 
features.  96 
Materials and methods 97 
GO preclinical mouse model samples 98 
Mouse samples used in the present work were obtained from a recent study [12], conducted 99 
in parallel in two independent animal housing units, under comparable SPF conditions. 100 
Animal procedures in center 1 were reviewed and approved by the Ethical Committee of 101 
King’s College London and conducted with Personal and Project licenses under United 102 
Kingdom Home Office regulations. Animal procedures in center 2 were reviewed and 103 
approved by North Rhine Westphalian State Agency for Nature, Environment and Consumer 104 
Protection (LANUV), Germany. Samples from the animal unit of King’s College London 105 
(UK) will be referred to as the “Center 1” and included a total of 5 TSHR-immunized mice 106 
(TSHR). Samples from the University of Duisburg-Essen (Germany) will be referred to as the 107 
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“Center 2”, including 10 TSHR-immunized (TSHR), 8 βgal plasmid controls (βgal) and 6 108 
untreated mice (included as a background control), as shown in Table 1. 109 
The GO immunization protocol has been previously described [13]. Briefly, 6-8 weeks old 110 
BALB/cOlaHsd female mice were immunized via intramuscular injection into each biceps 111 
femoris muscle [22] and electroporation of either the eukaryotic expression plasmid 112 
pTriEx1.1Neo-hTSHR (hTSHR289) (TSHR group) or the control plasmid pTriEx1.1Neo-β-113 
gal (plasmid-control, βgal group). All animals, whether TSHR or βgal controls, received a 114 
total of four plasmid injections at three week-intervals of the experiment (0, 3, 6, 9 weeks).  115 
Each mouse was anesthetized using isoflurane with a properly calibrated vaporizer 116 
throughout the immunization procedure (injection and electroporation). After the 117 
immunization, mice were carefully transferred to a recovery cage until fully recovered.  118 
Mice in Center 1 were maintained conventionally in open cages in one room and co-housed 119 
at a maximum of 3 animals per cage. In Center 2, the mice were co-housed according to their 120 
immunizations, 2-4 animals per individually ventilated cage in one room. All mice were 121 
provided by different outlets of the same supplier (Harlan Ltd or Harlan laboratories BV). In 122 
both centers, mice received autoclaved water and had been fed ad libitum similar commercial 123 
chow from different suppliers (Rat and Mouse no.1 Maintenance from Special Diet Services, 124 
LBS Biotech UK for Center 1 and Rat/Mouse Maintenance V1534-300 from Ssniff 125 
Spezialadiaten GmbH, Germany, for Center 2). Also the cage bedding was from different 126 
suppliers. 127 
All immunized and control mice in both locations were sacrificed nine weeks after the last 128 
immunization (18 weeks) to permit the development of the chronic phase of the disease in the 129 
TSHR group (Additional file 1: Figure S1). 130 
After sacrifice, murine intestines were snap-frozen and stored in sterile containers at −80°C. 131 
For subsequent analysis, whole intestines were thawed and directly afterwards placed on a 132 
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sterile padding. The organs were dissected into two or three parts and the content of all parts 133 
was scratched out from oral to aboral end with a sterile inoculation loop resulting in one 134 
sample per mouse, which was collected in a sterile container and frozen at -80°C until 135 
needed. Within the Center 2 only, fecal pellets of βgal and TSHR immunized mice were also 136 
collected before each injection (week 0, 3, 6, 9). Total DNA was extracted from fecal pellets 137 
as described below. 138 
Methods for: i) the evaluation of clinical symptoms, ii) the determination of the thyroid 139 
hormone thyroxine blood levels (fT4) and TRAB (both stimulating TSAb and blocking 140 
TSBAb) antibodies, iii) the measurement of the expansion of fat cells (adipogenesis) and 141 
muscular atrophy in the orbit have been already described [12]. A full description of the mice 142 
involved and samples collected in the present study is represented in Table 1. 143 
 144 
Table 1 Description of the mouse groups involved in this study 145 
No. of animals Immunization Centers Source Timepoint 
5 TSHR 1 Intestinal scraping T4 
10 TSHR 2 I.S./Feces T0-T4* 
8 βgal 2 I.S./Feces T0-T4* 
6 Untreated 2 I.S./Feces T4° 
 
A total of 23 female BALB/cOlaHsd, 6-8 weeks old mice were challenged either with the pTriEx1.1Neo-146 
hTSHR to induce disease (TSHR group) or with pTriEx1.1Neo-β-gal as a plasmid control group (βgal 147 
group). Independent SPF animal units were based in London (Center 1) and Essen (Center 2). An untreated 148 
group of 6 mice has been included as a background control. Samples collection comprised of intestine 149 
scraping (I.S.) from Center 1 and both fecal pellets and I.S. within the Center 2. *Fecal pellets of βgal and 150 
TSHR immunized mice have been collected before any immunization (T0) and during the time course of 151 
the immunization protocol until the sacrifice (T4), as represented in Additional file 1: Figure S1. 152 
°Untreated mice were sampled at T4 before (fecal) and after the sacrifice (intestinal scraping).  153 
Traditional microbial cultures of mouse gut contents  154 
A total of 29 scraped intestinal samples (Table 1) derived from Center 1 and Center 2 were 155 
analyzed. One gram of feces per mouse was diluted in 9 ml pre-reduced maximum recovery 156 
diluent (CM0733, Oxoid, Basingstoke, United Kingdom) with 20% v/v glycerol and the 157 
solution was mixed by vortexing for 5 s. Afterwards, 10-fold serial dilutions were prepared, 158 
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and 100µl of each dilution was plated onto different culture media under aerobic or anaerobic 159 
conditions (Anaerobic Workstation, AW400SG, Elektrotek, Keighley, West Yorkshire, 160 
United Kingdom). Specific media, culture conditions and dilution used to isolate different 161 
bacteria are listed in Additional file 2.  162 
Bacteria were identified by Gram staining, colony morphology, the presence of spores, 163 
catalase reaction and partially by the API system (BioMerieux, Marcy-l’Étoile, France). 164 
Viable bacterial cell counts were enumerated and all counts were recorded as the numbers of 165 
log 10 colony forming units per gram of sample. Counts data were Box-Cox transformed 166 
before statistical analysis [23]. Mouse groups were compared through the Analysis of 167 
variance (one-way ANOVA) and Tukey’s multiple comparisons test with adjusted P values.  168 
Extraction of total DNA from gut contents and feces and 16S rRNA gene sequencing 169 
A total of 29 scraped intestinal samples and 96 fecal pellets were individually placed in 2mL 170 
tubes prefilled with 0.1mm silica and zirconia bead mix (Benchmark Scientific, Edison, 171 
USA), dissolved in 1mL InhibitEX buffer (Qiagen Ltd, West Sussex, UK) and vortexed until 172 
homogenized. A bead-beating step (Beadbug microcentrifuge homogenizer, Benchmark 173 
Scientific, USA) was applied for 3 x 60sec at 5m/s with 5 min rest in-between. The DNA 174 
extraction has been performed with QiAmp Fast DNA Stool Mini kit (Qiagen Ltd, UK), 175 
following the manufacturer’s instruction. Total genomic DNA was eluted in sterile 176 
microcentrifuge tubes and quantified by Qubit Fluorimetric Quantitation (ThermoFisher 177 
Scientific Ltd, UK), following manufacturer's instructions. DNA aliquots were kept at -20°C 178 
until used. Sequencing of the variable regions of the 16S rRNA gene was performed at 179 
Research and Testing Laboratory LLC. (Lubbock, Texas, USA). Primers used to amplify the 180 
V1-V2 regions of 16S rRNA gene were: 28F (5’-GAGTTTGATCNTGGCTCAG-3’) and 181 
388R (5’-TGCTGCCTCCCGTAGGAGT-3’). Sequencing was performed using an Illumina 182 
Miseq (Illumina, San Diego, USA), with 10K paired-end sequencing protocol.  183 
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Processing and statistical analysis of metataxonomic data 184 
Processing of the sequences was performed using Mothur v1.36, to reduce possible PCR 185 
effects and to cluster sequences into Operational Taxonomic Units (OTUs) at the 97% 186 
identity cut-off and provide the taxonomic annotations [24]. Paired-end reads (R1 and R2) 187 
were joined for each sample using the Mothur function “make.contigs” and trimmed at the 188 
2.5%-tile and 97.5%-tile on the distribution lengths of the amplicons. Sequences with any 189 
ambiguities (i.e. Ns) were removed by setting parameter N=0. Filtered sequences were 190 
aligned against the SILVA 16S rRNA gene reference database (http://www.arb-silva.de). 191 
Removal of chimera sequences was done with the Uchime tool [25]; singleton and non-192 
bacterial sequences (e.g. Archaea, Eukaryotic, Chloroplast and Mitochondria) have been 193 
removed from the analysis. The taxonomic assignment from phylum to genus level of the 194 
processed sequences was done using the Ribosomal Database Project (RDP) Naïve Bayesian 195 
Classifier, using Trainset 14 with a cut-off of 80% [26]. FastTree (version 2.1.7) has been 196 
used to build a phylogenetic tree, using an approximated maximum likelihood solved by 197 
Jukes-Cantor evolutionary model [27]. To reduce the effect of possible different sampling 198 
methods and to obtain comparable sequencing libraries, each sample library has been 199 
subsampled based on the smallest library size. OTUs with less than 10 counts have been 200 
excluded from the dataset and grouped as “OTU_low”, and the analysis has been performed 201 
collapsing OTUs at the phylum-genus levels. Statistical analysis was performed in R 202 
(Version 3.2.2) and STAMP tool for metataxonomic data analysis [28].  203 
Alpha diversity indices (Observed OTUs, Chao1, ACE and Shannon) were calculated within 204 
samples from Mothur and tested for association with covariates (e.g. locations and 205 
immunizations) using a linear model, followed by Tukey’s Honest Significant Difference 206 
(HSD) post-hoc analysis.  207 
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Beta diversity was estimated using the Unifrac weighted distance to compare bacterial 208 
communities among samples [29], and represented in a Non-Metric Dimensional Scaling 209 
(NMDS) plot. The permutational multivariate analysis of variance (PERMANOVA) was 210 
calculated through the Adonis function [30] in R Vegan package (using 999 permutations) 211 
and was used to test the association between the microbiota composition and the covariates 212 
(e.g. location of the laboratories or immunizations).  213 
The hierarchical clustering of genera was performed using the Spearman distance and the 214 
Ward agglomeration method. Statistical tests with P≤0.05 were considered as significant. 215 
Over multiple timepoints, the effects of time, immunizations and their interactions, have been 216 
estimated on the fecal microbiota composition, all by means of the following linear model:  217 �௜௝௞ = � + ��݉�௜ +  �݉݉ݑ݊�ݖ�ݐ�݋ ௝݊ + ሺ��݉� ∗  �݉݉ݑ݊�ݖ�ݐ�݋݊ሻ௜௝ + �௜௝௞ 218 
where y is the vector of either alpha-diversity Chao or Shannon indices, or of the 219 
Firmicutes/Bacteroidetes ratio calculated from the relative abundances in each sample at each 220 
timepoint; μ is the overall mean; time is the effect of timepoint in classes (T0, T1…T4); 221 
immunization is the type of immunization (either the TSHR or βgal). The factorial interaction 222 
between immunization and time has also been included in the model; e is the vector of 223 
residual effects. Comparison between βgal and TSHR immunizations at each timepoint was 224 
made using the pairwise T-test with Benjamini-Hochberg correction for false rate discovery 225 
(FDR).   226 
To test differences in phylum and genus counts between immunizations and timepoints, the 227 
same model was used in the generalized linear model (GLM) implemented in the EdgeR 228 
package [31]. Pairwise comparisons of phylum and genus counts between timepoints and 229 
immunizations have been assessed with Fisher’s Exact Test in EdgeR package. 230 
Correlations of either the taxonomy counts (phylum and genus relative abundances) or the 231 
microbial counts from the traditional culture approach and disease features, such as anti-232 
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TSHR antibodies and thyroid hormone thyroxine levels (fT4), orbital adipogenesis or 233 
muscular atrophy values, were estimated using the Spearman correlation coefficient (Rho) 234 
and represented in a correlation plot, using the R Corrplot package. Additional statistical 235 
methods are described in Additional file 2.  236 
Results  237 
Sequencing metrics 238 
From 16S rRNA gene sequencing (V1-V2 regions), a total of 5,333,798 reads were obtained 239 
which reduced to 4,047,186 reads after quality filtering. Following alignment, we obtained an 240 
average of 20,534 reads per sample, ranging from 3,502 to 134,901. Subsampling per library 241 
size resulted in a 96% average coverage per OTU definition at 3,052 reads per sample. The 242 
averaged coverage and subsampling was sufficient to describe gut bacterial communities 243 
according to sequence-based rarefaction curves (data not shown). 244 
We identified a total of 4,281 OTUs: 1,037 OTUs had more than 10 counts across samples, 245 
and were retained.  246 
Comparative analysis of the gut microbiota of GO preclinical mouse models in different 247 
centers  248 
To assess whether the microbiota has an impact on the GO mouse model in different 249 
laboratories, we compared the gut microbial contents of 5 TSHR mice from Center 1 and 10 250 
TSHR immunized BALB/c female mice from Center 2, after sacrifice (T4).  251 
Comparison of the alpha diversity indices showed a significant reduction in the richness 252 
(P=0.01), but not in the diversity of the Center 2 microbial community (P>0.05, Figure 1A). 253 
The gut microbiota composition from the two centers showed a good separation according to 254 
the Spearman distance and Ward hierarchical clustering (Figure 1B), and a PERMANOVA 255 
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test on the weighted Unifrac distances revealed a spatial difference between bacterial 256 
communities (P=0.005 with 999 permutations, Figure 1C). 257 
At a phylum level, Bacteroidetes and Firmicutes were the most represented of the 7 phyla 258 
identified, with no differences between them in the two centers (P=0.99). Lactobacillaceae, 259 
Ruminococcaceae and Porphyromonadaceae families were more abundant in Center 2 than 260 
in Center 1 TSHR mice (P<0.01, Figure 1D). We observed significant differences in the 261 
abundance of eighteen genera between the two centers, as detailed in Table 2.  262 
From the traditional microbial culture of the gut contents, we observed differences in yeasts 263 
(P=0.03186), Bacteroides (p<0.0005) and total anaerobes (P=0.00081) counts, which were 264 
found to be enriched in the Center 1 compared with the Center 2 TSHR mice (Table 3). 265 
Cultures from mouse intestinal scraping of the Center 2 did not contain any total clostridia, 266 
Bacteroides or yeasts, and we were able to culture enterobacteria, E. coli and coliforms from 267 
only one mouse from this group. E.coli and coliforms were also the least abundant in the 268 
Center 2 TSHR mice (Figure 1E). Furthermore, since Yersinia enterocolitica has been 269 
implicated in GD pathogenesis [32] we used selective agar plates for Yersinia sp. but no 270 
Yersinia colonies grew. 271 
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Table 2 Genera differentially abundant between Center 1 (n=5) and Center 2 (n=10) TSHR 272 
immunized mice intestinal scraped samples 273 
 274 
Genera  Center 1: mean freq. (%) Center 2: mean freq. (%) P values  
Allobaculum 1.001 0.003 0.042 
Alloprevotella 6.135 0.432 0.003 
Bacteroides 9.370 1.525 0.017 
Bifidobacterium 0.668 0.006 0.003 
Clostridium XI 0.840 0.000 0.005 
Coprobacter 1.835 4.226 0.033 
Fusicatenibacter 0.989 3.295 0.032 
Guggenheimella 0.006 0.169 0.011 
Helicobacter 0.200 0.000 0.024 
Intestinimonas 0.097 0.861 0.000 
Lactobacillus 2.304 18.632 0.030 
Lactonifactor 0.023 0.401 0.025 
Meniscus 1.149 0.000 0.000 
Oscillibacter 0.640 1.748 0.011 
Parabacteroides 0.292 0.031 0.015 
Pseudoflavonifractor 0.154 0.466 0.028 
Rikenella 3.921 1.216 0.004 
Turicibacter 3.629 0.000 0.002 
ANOVA with Tukey’s HSD post-hoc analysis (95% confidence interval), generated with STAMP. 275 
Mean freq: mean frequency (%).  276 
 
Table 3 Traditional microbiology results from TSHR-immunized mouse intestinal scraping 277 
from Center 1 (n=5) and Center 2 (n=10)  278 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b.d.l.: below detection limit. Detection limits are the following according to the agar used: 1000 279 
CFU/g feces for Bacteroides, 100 CFU/g feces for E.coli and coliforms as well as for enterobacteria, 280 
and 10 CFU/g feces for total clostridia and yeasts, respectively. Microbiological counts were Box-Cox 281 
transformed. P values obtained by linear regression.  282 
Microbial target Center 1: mean counts  Center 2: mean counts      P values 
Bacteroides 1.15E+05 b.d.l. 0.000 
Bifidobacteria 6.41E+06 1.32E+06 0.057 
Coliforms 3.27E+02 1.15E+03 0.453 
E.coli  b.d.l. 8.45E+02 0.499 
Enterobacteria b.d.l. 6.82E+02 0.499 
Enterococci 1.74E+05 6.10E+06 0.247 
Lactobacilli 1.93E+06 4.68E+06 0.725 
Staphylococci 1.31E+05 3.77E+05 0.175 
Total aerobes 4.18E+05 9.90E+06 0.370 
Total anaerobes 6.75E+06 7.39E+05 0.001 
Total Clostridia 2.46E+04 b.d.l. 0.165 
Yeast 8.72E+01 b.d.l. 0.031 
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Gut microbiota differences in immunized and control mice within the Center 2 283 
To observe the possible contribution of the gut microbiota in the disease, we compared the 284 
gut microbiota composition between immunization groups in mice within the Center 2. No 285 
significant differences were observed in alpha diversity indices among immunizations, apart 286 
from the Abundance-based Coverage Estimator (ACE) index between untreated and TSHR 287 
groups (Figure 2A, P=0.01). The ACE index relies on the presence of rare OTUs [33], which 288 
were more abundant in the untreated group compared to the plasmid-immunized mice. The 289 
βgal group showed a slightly skewed distribution of the Shannon index when compared to the 290 
others; however, the post-hoc comparison was not significant. 291 
The non-metric dimensional scaling (NMDS) of the weighted Unifrac distances matrix 292 
showed a separation of the three immunization groups, also confirmed by the permutation test 293 
(P<0.01, 999 permutations; Figure 2B). βgal bacterial communities were closer to those of 294 
the untreated mice, while we observed a spatial shift of the TSHR immunized bacterial 295 
communities. 296 
OTUs from Bacteroidetes and Firmicutes phyla were the most abundant among the phyla 297 
identified (Figure 2C) and showed a different distribution pattern among immunized groups. 298 
In particular, Firmicutes counts were higher in TSHR immunized mice (P=0.05) and 299 
Bacteroidetes were found to be higher in the untreated group (P=0.012). At a genus level, 300 
eight genera were differentially abundant between TSHR and βgal groups; three genera 301 
between TSHR and the untreated group and four genera between βgal and the untreated 302 
group (Additional file 3: Table S1). We found an enrichment of OTUs of Acetitomaculum 303 
genus in the βgal group compared to both TSHR (P=0.004) and the untreated group 304 
(P=0.003); an enrichment of Lactobacillus OTUs in the TSHR compared to the untreated 305 
group (P=0.018) and a reduction of Bacteroides counts in TSHR when compared to the βgal 306 
group (P=0.047). However, no significant differences were observed among immunized 307 
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groups and in pairwise comparisons generated by the traditional bacterial culturing approach 308 
(Additional file 3: Table S2). 309 
In the scraped intestinal samples, we did not observe a cage effect on the composition of the 310 
large intestine microbiota (PERMANOVA P>0.05; Figure 2D). 311 
Dynamics of fecal microbiota during the immunization protocol 312 
To assess whether the immunization plasmids and the duration of the protocol could have 313 
influenced the gut microbiota composition, we sequenced the bacterial 16S rRNA gene from 314 
the fecal pellets of the βgal and TSHR group from the baseline (T0) for 18 weeks afterwards, 315 
until the end of the experiment (T4).  316 
We observed a significant increase of the richness (Chao index, figure 3A; P=0.02) and the 317 
diversity (Shannon index, figure 3B) over time, which was less apparent in the TSHR 318 
immunized group. Significant differences regarding of richness between TSHR and βgal have 319 
been observed at T4 (P=0.027, Table 4). The Shannon index of diversity, on the contrary, 320 
was significantly different between TSHR and βgal immunization at T1 (P=0.023, Table 4).  321 
Table 4 Summary of the statistics from the time-course analysis of the fecal microbiota 322 
during the immunization protocol (T0-T4) and between immunizations (βgal and TSHR)  323 
 324 
Index 
ANOVA model TSHR vs. βgal group 
Immunization Time Time*Immunization T0 T1 T2 T3 T4 
Chao  0.006 0.02 0.8 0.75 0.066 0.28 0.33 0.027 
Shannon 0.054 0.28 0.47 0.44 0.023 0.35 0.35 0.29 
Firm:Bact 0.406 0.0003 0.16 0.39 0.028 0.46 0.2 0.26 
 325 
Firm:Bact, Firmicutes/Bacteroidetes ratio. ANOVA model as previously described. Pairwise 326 
comparison between βgal and TSHR in each time point has been made with a pairwise T-test with 327 
Benjamini-Hochberg correction for FDR. 328 
 329 
The murine fecal microbiota comprised Bacteroidetes and Firmicutes phyla predominantly 330 
(Figure 4C); followed by Tenericutes, Proteobacteria Deferribacteres and Candidatus 331 
Saccharibacteria phyla. The Firmicutes/Bacteroidetes ratio has been used to describe the shift 332 
in the gut microbiota associated with ageing [34] and also in disease conditions such as 333 
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obesity [35]. The ratio showed differences amongst the timepoints of the experimental 334 
procedure (P<0.01) and between TSHR and the βgal group after three weeks from the first 335 
injection (T1, P=0.011; Figure 3C).  336 
We fitted a generalized linear model (GLM) to compare the taxonomic counts at different 337 
timepoints within each group independently (either TSHR or βgal). Thirty-four genera have 338 
been identified as differentially abundant among all timepoints in the TSHR immunized 339 
group (Additional file 4: Table S1), while 25 were found in the βgal group (Additional file 4: 340 
Table S2). We observed differences in the taxonomic profile between TSHR and βgal groups 341 
at each timepoint using an exact test (EdgeR). Once again T1 was identified as the timepoint 342 
with the highest number of genera differentially expressed, as illustrated by the diversity 343 
indices (Additional file 4: Table S3). 344 
In contrast to data obtained from the gut microbiota (Figure 2D), a cage effect was observed 345 
in the fecal microbiota, in particular, in interaction with time (P=0.001) and immunization 346 
(P=0.002; Additional file 5: Figure S1). The latter is probably due to the mice being caged 347 
according to the type of plasmid injection they received, but we also observed a significant 348 
difference within the same immunization group (e.g. TSHR in cage 4 and cage 5, P=0.01).  349 
Correlating the gut microbiota composition with clinical features and differences in GO 350 
development  351 
We then investigated possible correlations between disease features, such as anti-TSHR 352 
antibodies, thyroxine levels (fT4), orbital adipogenesis and muscular atrophy, and the gut 353 
microbiota composition to determine whether it contributes to the heterogeneity of induced 354 
responses, summarized in Additional file 1: Table S1.  355 
Within the Center 1 TSHR-immunized group, we found that OTUs from Firmicutes and 356 
Bacteroidetes negatively correlated to each other (Rho=-1, P<0.0001). A positive correlation 357 
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between levels of TSAb and Deferribacteres phylum, which include one-genus 358 
Mucispirillum, was found (Rho=0.92, P=0.028; Figure 4A).  359 
From those genera differentially abundant between TSHR-immunized mice from Center 1 360 
and Center 2 (Table 2), identified via metataxonomics, we observed a strong negative 361 
correlation of the Firmicutes genus Intestinimonas and the levels of TSBAb in the Center 1 362 
(Rho=-0.89, P<0.05), but not in the Center 2 counterpart (Figure 4B). No significant 363 
correlation was observed between OTUs from the genus Intestinimonas and levels of TSAb 364 
or levels of free thyroxine hormone (fT4; data not shown).  365 
On the contrary, the Box-Cox transformed counts from the traditional microbiology did not 366 
show any significant correlation with the disease features described (data not shown). 367 
Within the Center 2, Bacteroidetes and Firmicutes negatively correlated to each other (Rho=-368 
0.99, P<0.0001; Figure 5A). We also found a significant positive correlation (Rho=0.6, 369 
P=0.009) between the OTUs from the Firmicutes and the orbital adipogenesis value and a 370 
negative correlation of this value with the phylum Bacteroidetes (Rho= -0.57, P=0.014). As 371 
expected, these correlations were specific to the TSHR immunized mice (Figure 5B). The 372 
correlation pattern we found (Firmicutes positively correlated, Bacteroidetes negatively 373 
correlated) was also recapitulated at the genus level. Among the genera of the Firmicutes, 374 
three, within the Clostridia family (Butyricicoccus, Parvimonas and Fusibacter) and the 375 
genus Lactobacillus were correlated positively with adipogenesis; while three Bacteroidetes 376 
genera (Anaerophaga, Paraprevotella and Tannerella) correlated negatively with the orbital 377 
adipogenesis values (Figure 5C). 378 
A strong positive correlation (Rho=0.82, P=0.007) was observed between orbital 379 
adipogenesis and the total anaerobes counts obtained from the traditional microbial cultures 380 
of TSHR immunized mice, but not in the controls (Figure 5D). Moreover, from the traditional 381 
microbial cultures data, we observed correlations with other disease features, specifically in 382 
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the TSHR group. We observed strong positive correlations between the muscular atrophy 383 
values and the cluster of lactobacilli (Rho=0.74, P=0.03), enterococci (Rho=0.8, P=0.02), 384 
bifidobacteria (Rho=0.76, P=0.03) and coliforms (Rho=0.73, P=0.04). Levels of free 385 
thyroxine (fT4) were positively correlated with lactobacilli (Rho=0.64, P=0.05) and 386 
staphylococci (Rho=0.77, P=0.016).  387 
Discussion   388 
Animal models have been invaluable in dissecting the mechanisms causing loss of immune 389 
tolerance leading to autoimmune conditions such as GD. Thus, we aimed to test the 390 
hypothesis that the gut microbiota may affect both outcome and reproducibility of induced 391 
autoimmune disease, such as reported in the recent research article of Berchner-Pfannschmidt 392 
and co-workers [12]. 393 
We observed significant differences in the diversity and spatial organization of the gut 394 
microbiota of female TSHR-immunized BALBc mice in two independent SPF units. We also 395 
demonstrated disease-associated microbial taxonomies and correlation with ocular disease, 396 
suggesting that the gut microbiota have contributed to the heterogeneity of induced response 397 
in the two locations, which further supports our hypothesis. 398 
Animals were maintained in similar conditions. We are confident that there were no 399 
infections ongoing at the moment of sampling, since animals in both centers were routinely 400 
tested for the presence of viruses, mycoplasma and parasites (see Additional File 1: Table 401 
S2); moreover, housing facilities had comparable SPF conditions. Animals were from the 402 
same supplier but in different countries (Harlan Ltd. for Center 1 and Harlan Lab. BV for 403 
Center 2), had received autoclaved water and had been fed similar commercial chow, with the 404 
exception that food pellets provided in Center 2 contained twice the amount of iodide 405 
compared to Center 1 food (see Additional File 1: Table S3). Although iodide excess can be 406 
associated with abnormal thyroid function, we do not consider that this dietary variation is 407 
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enough to explain the results (i.e. elevated thyroxine levels were apparent in the Center 1 but 408 
not in Center 2 mice). The effect of iodine has been studied in the NOD mouse which 409 
spontaneously develops autoimmune thyroiditis. Vecchiatti and colleagues [36] reported that 410 
excess iodine (0.2 mgs/mouse/day) increased the incidence and severity of disease; however, 411 
the BALB/c mice in our study did not display thyroiditis. A transgenic NOD mouse 412 
expressing the human TSHR-A subunit is able to develop antibodies to the human TSHR and 413 
this too is exacerbated by iodine excess [37] but at levels far greater than in the chow used in 414 
Centers 1 and 2. We also considered whether iodine could affect the gut microbiota, in view 415 
of its use as an antiseptic, but all the studies we found were in this context, rather than the 416 
effect of dietary iodine on symbionts. The importance of SPF conditions is indicated by a 417 
previous study which failed to reproduce a GO animal model, despite using mice from the 418 
same supplier and identical bedding, water and chow [10]. However even SPF may be 419 
inadequate since differences were found in the gut microbiota of C57BL/6 colonies bred in 420 
two different rooms of the same SPF facility [38], fortunately mice in our study were all 421 
housed in the same room. 422 
Cage effects were apparent in the fecal microbiota results, which highlight the importance of 423 
studying the gut microbiota instead when comparing autoantigen (TSHR)-immunized and 424 
control mice, which is in the close proximity of the intestinal mucosa and the immune 425 
system, enabling us to explore its relationship with disease features.    426 
We observed several disease-associated taxonomies; the abundance of the newly described 427 
butyrate-producing genus Intestinimonas [39] was reduced in the Center 1 group compared to 428 
Center 2 and correlated negatively with TSBAb. The Intestinimonas species butyroproducens 429 
has a unique ability to produce butyrate from lysine and is involved in the detoxification of 430 
Advanced Glycosylation End (AGE) products such as fructoselysin, which have been linked 431 
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to type-1 diabetes [40], although we are unaware of any link between butyrate-producing 432 
bacteria and thyroid autoimmunity.  433 
The TSHR immunized group developed some signs of GO and their gut microbiota had 434 
increased OTUs of the phylum Firmicutes but decreased Bacteroidetes compared with 435 
controls. This mirrors our preliminary data in human disease where we observed a dramatic 436 
reduction in the Bacteroides genus in GD patients when they develop GO (INDIGO 437 
publishable summarya). 438 
We also obtained a positive correlation between several Firmicutes counts, such as Clostridia 439 
and Bacilli, with orbital adipogenesis in Center 2 TSHR-immunized mice. Million and co-440 
workers have previously reported a positive correlation between OTUs from the Firmicutes 441 
and weight-gain/obesity in both animal models and humans [41]. Interestingly, the role of the 442 
genus Lactobacillus and its products in either triggering or protecting from adipogenesis has 443 
been debated and seems to be species-specific.  444 
In the present work, we could exclude a possible gain-of-weight relationship with the 445 
adipogenesis value calculated in the orbit since no changes in mouse weights have been 446 
observed during the development of the chronic phase of the disease (data not shown). 447 
Furthermore, molecular mechanisms driving obesity and orbital adipogenesis may well be 448 
different, since the latter is derived from the neural crest and the gut microbiota may have 449 
varying effects on different fat depots [42]. 450 
Our time-course analysis revealed that time had a dramatic role in shaping the fecal 451 
microbiota of the female mice which were 6-8 weeks-old at the outset and 24-26 weeks at the 452 
end of the experiment, confirming the work of McCafferty and colleagues [43]. The richness 453 
and diversity of βgal control mice increased with age but this was less apparent in TSHR 454 
immunized animals. Significant differences in microbiota composition between control and 455 
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TSHR immunizations were most apparent 3 weeks after the first immunization, at the 456 
initiation of the induced immune response. 457 
Our control group comprised mice immunized with the βgal expression plasmid in which we 458 
observed a slight skew in the microbiota richness and diversity which may be caused by the 459 
systemic overexpression of the β-galactosidase enzyme, whose natural role is in glycan 460 
metabolism, e.g. the hydrolysis of the lactose to galactose and glucose [44]. Kaneda and 461 
collaborators reported a βgal overexpression peak in the muscle fibers following 462 
electroporation from five days to 2 weeks after the injection [45].  463 
 It may be that the increased OTUs of the Firmicutes genus Acetitomaculum was specifically 464 
triggered by the product of the βgal enzymatic reaction over time (Additional file 4: Table 465 
S2). This effect merits further investigation but we are confident that the βgal vector plasmid 466 
provides the optimum control group since its microbial communities were more closely 467 
related to that of the naïve non-immunized group than to TSHR immunized mice. Of interest, 468 
TSHR-immunized mice in Center 2 were more similar to TSHR-immunized mice from 469 
Center 1 (P=0.2) than βgal (P=0.024), than untreated (P=0.04) mice in their own center 470 
(Additional File 6: Figure S1). 471 
The results we obtained using 16S rRNA gene metataxonomics and via the traditional 472 
microbial culture approach were largely similar, with relatively few differences. Microbial 473 
cultures revealed significantly higher yeast counts (P=0.03186) in Center 2 TSHR immunized 474 
mice - which obviously could not be seen via the bacterial metataxonomics - and a nearly 475 
significant difference in the Actinobacteria genus Bifidobacterium (P=0.057), which was not 476 
detected in our metataxonomics data. Primers based on the V1-V2 regions of the 16S rRNA 477 
gene did not detect Bifidobacterium OTUs. Consequently, we applied a new set of primers 478 
(28F-combo) with which we observed a significant enrichment of bifidobacteria counts in the 479 
Center 2 (Additional file 7: Figure S1), in agreement with the microbial culture results. 480 
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 481 
Conclusions 482 
In conclusion, our results indicate a role for the gut microbiota in modulating the 483 
heterogeneity apparent in the TSHR-induced model of GD and GO. In our next study we will 484 
report the effects on our induced model of modifying the gut microbiota using antibiotics, 485 
probiotics and fecal material transfer.  486 
Our future studies will investigate whether the presence, absence or amounts of certain 487 
bacteria or yeast have the ability to directly alter the immune balance between the Treg anti-488 
inflammatory response and the Th17-mediated pro-inflammatory response in the gut mucosa 489 
as has been reported in models of other autoimmune diseases [22,46]. Results of these 490 
experiments could then be confirmed by colonization studies in gnotobiotic animals. Factors 491 
such as level of dietary iodine intake and age of mice at immunization, which may both alter 492 
the gut microbiota and/or immune responsiveness, are also warranted.493 
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Figure legend   
 
Fig. 1 Comparative analysis of the gut microbiota in independent animal units. a Box and whisker 
plot of the alpha diversity indices for richness (Chao1 and observed OTUs indices) and evenness 
(Shannon index) of the bacterial communities in TSHR immunized mice housed in Center 1 (blue) 
and Center 2 (red), respectively. Tukey’s HSD post-hoc: Chao1, P=0.01; Observed OTUs, P<0.001; 
Shannon, P=0.08. b Annotated heatmap based on Spearman distance and Ward hierarchical clustering 
of the top 30 genera shows how well the two locations cluster together. Taxonomy explanation 
includes genera, family and phylum, which are entered in order of abundance. Genus abundance is 
described by the change in the intensity of the grey color, as annotated. c Multidimensional scaling 
plot (MDS) based on the weighted Unifrac distances between the two animal units. PERMANOVA 
with 999 permutations P=0.005. d Differentially abundant family from a pairwise comparison with 
Welch’s t-test with 95% confidence intervals (STAMP). e Box and whisker plot culture results from 
intestinal scraped samples derived from TSHR-immunized mice from Center 1 and Center 2. Results 
are expressed as a Log(x+1) transformed colony-forming-units/gram feces (cfu/g). P-values: * 
P<0.05; ** P<0.001; *** P<0.005. 
 
Fig. 2 Gut microbiota composition in TSHR immunized mice and control mice in Center 2 at final 
timepoint. a Box and whisker plot describing the measurement of alpha diversity (Chao, ACE and 
Shannon indices). b Non-metric dimensional scaling (NMDS) plot of weighted Unifrac distances 
showed a spatial separation of microbial communities according to the immunizations. 
PERMANOVA based on 999 permutations P=0.001. c Boxplot of the phylum counts according to 
immunizations. ANOVA on phylum counts BH adjusted P<0.0001 and pairwise T-test between 
Bacteroidetes-Firmicutes counts adjusted P=0.0003. d Non-Metric Dimensional Scaling (NMDS) plot 
based on weighted Unifrac distances shows spatial separation of the microbial community according 
to the immunization and caging within the Center 2. Mice were co-housed according to their 
immunization at a maximum of 4 animals; cages are described by different shapes as in the legend. 
No significant difference in cage effect is observed. PERMANOVA based on cage effect (999 
permutations) for all comparisons P=0.12. P-values: * P≤0.05; ** P=0.01. 
 
Fig. 3 Time-course analysis of GO preclinical fecal microbiota during the immunization protocol. 
Box and whisker plot of alpha diversity such as Chao, a, and Shannon, b, indices showed differences 
over time. c Phylum dynamics over time and between immunizations. Firmicutes and Bacteroidetes 
were the most abundant phyla, showing differences with time and immunizations. Significant 
differences among timepoints have been observed at the Firmicutes/Bacteroidetes ratio, in particular 
between the baseline T0 and the last timepoint T4, but not related to immunization. A significant 
difference in the ratio was observed after three weeks from the first injection (T1) between βgal and 
TSHR. P-values: * P≤0.05; ** P=0.01. 
 
Fig. 4 Correlating the gut microbiota and disease features in Center 2 TSHR group. a Spearman 
correlation coefficient strength (Rho) of phylum counts from TSHR mice in Center 2. Firmicutes and 
Bacteoridetes showed a strong negative correlation between each other. A positive correlation 
between the one-genus phylum Deferribacteres and the level of thyroid-stimulating antibodies 
(TSAb) has been observed. Correlations with P<0.05 are shown and strength of the Rho coefficient is 
represented by the change in the colour intensity. fT4, free thyroid hormone thyroxine levels; TSAb, 
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thyroid stimulating antibodies; TSBAb, thyroid-stimulating blocking antibodies (as a percentage 
values). b Enriched Firmicutes genus Intestinimonas between Center 1 (blue) and Center 2 (red) 
showed a strong negative correlation with the percentage of thyroid-stimulating blocking antibodies 
(TSBAbs) at 95% confidence interval in Center 1 (Rho=-0.8, P=0.04), but not in Center 2.  
 
Fig. 5 Correlation of the gut microbiota composition with clinical features and differences in Center 2 
mice. a Correlation plot of phyla and the orbital adipogenesis value. Spearman correlation coefficient 
strength (Rho) as indicated by the colored bar. Firmicutes and Bacteoridetes showed a strong negative 
correlation between each other. A positive correlation between Firmicutes and a negative correlation 
with Bacteroidetes OTUs and the adipogenesis value (calculated in the orbit) has been observed. 
Adipogenesis clustered closer to the Firmicutes and Bacteroidetes value according to the complete 
linkage method for hierarchical clustering. Only P<0.05 are shown. b Positive strong correlation of 
the Firmicutes/Bacteroidetes ratio with the adipogenesis value (calculated in the orbit) resulted 
significant in TSHR immunized group but not in the βgal group. c Spearman correlation coefficient 
(Rho) of genera among phyla Bacteroidetes and Firmicutes and the orbital adipogenesis values. The 
strength of the correlation coefficient is represented on x-axis: bars on the left represent a negative 
correlation coefficient, while bars on the right represent a positive correlation coefficient. Correlations 
with P<0.05 are shown; order of entrance depends on their P values: * P<0.05; ** P<0.1; *** 
P<0.005. d Spearman correlation coefficient plot of the Box-Cox transformed microbiological counts 
and disease features in Center 2 TSHR immunized mice. Features clustering was according to the 
complete linkage method for hierarchical clustering. Only correlations with P<0.05 are shown and 
strength of the correlation coefficient is represented by the change in the color intensity. fT4, free 
thyroid hormone thyroxine levels; TSAb, thyroid stimulating antibodies; TSBAb, thyroid-stimulating 
blocking antibodies (as a percentage values). 
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Figure S1 
 
 
 
 
Schematic representation of the GO immunization protocol and sample collection. Female 
BALB/cOlaHsd, 6-8 weeks old mice were immunized via intramuscular injection and electroporation 
of either the eukaryotic expression plasmid pTriEx1.1Neo-hTSHR (hTSHR289) to develop signs of 
GO (TSHR A-subunit) or the control plasmid pTriEx1.1Neo-β-gal, as a plasmid-control group (βgal). 
Each animal received a total of four plasmid injections at three week-intervals. All immunized and 
control mice were sacrificed 9 weeks after the last immunization to permit the development of the 
chronic phase of the disease in the TSHR immunized group. Fecal pellets have been collected during 
the time course of the immunization trial from the baseline (T0) and before any other injection until 
the end of the procedure (T4). After euthanasia, the microbial content residing on the colonic mucosa 
has been collected through scraping.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table S1 Summary of disease characteristics induced in mice in Center 1 and Center 2 using TSHR 
expression plasmid illustrating the heterogeneity of response.  
 
Disease Feature Center 1 (n=5) Center 2 (n=10) 
TRAB (%) 5/5 positive 10/10 positive 
TSAb (pmol/mL) 2/5 positive 4/10 positive 
TSBAb (%) 3/5 positive 9/10 positive 
Thyroxine (mg/dL) 2/5 hyperthyroid 10/10 euthyroid 
Orbital adipogenesis Not available 4/8 increased 
Orbital muscle atrophy Not available 3/8 significantly increased 
Thyroid Histology 2/5 thyroid focal infiltration 10/10 normal histology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2 Quarterly Health Screen Reports on viral, bacterial, mycoplasma and parasite screen in both 
centers.  
 
Microbiological screening Center 1 Center 2  
MNV (Murine Norovirus) negative positive 
Helicobacter negative positive 
Trichomonas sp. negative positive 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table S3 Composition of the commercial chows provided ad libitum in Center1 and Center2   
 
 Center 1  Center 2  
Product Name  Rat and Mouse no.1 
Maintenance  
Rat/Mouse Maintenance 
V1534-300 
Supplier Special Diet Services, LBS 
Biotech UK 
Ssniff Spezialadiaten 
GmbH, Germany 
Protein (%) 14.38 19.00 
Fat (%) 2.71 3.30 
Fiber (%) 4.65 4.90 
Ca (%) 0.73 1.10 
P (%) 0.52 0.70 
Na (%) 0.25 0.24 
I (mg/Kg) 1.2 2.2 
Gross energy (MJ/Kg) 14.74 16.3 
Metabolizable energy (MJ/Kg) 10.74 12.8 
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Supplementary methods 
Media and conditions for microbial cultures  
The following media, culture conditions and dilutions were used to isolate different bacteria in this study: 
Horse blood agar (Horse blood agar base No.2 (CM0271) with added Defibrinated Horse Blood (SR0050); 
both Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 24 hours at 36 +/- 1 
°C. Dilutions from 10-2 to 10-7 were made and total cell count was measured. MacConkey agar No. 3 (CM0115, 
Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 24 hours at 36 +/- 1 °C. 
Dilutions from 10-2 to 10-7 were made and Enterobacteriaceae (red colonies with bile precipitation and straw 
coloured colonies) were counted. Slanetz and Bartley Medium (CM0377, Oxoid, Basingstoke, United 
Kingdom) was incubated under aerobic conditions for 24 hours at 36 +/- 1 °C. Dilutions from 10-2 to 10-7 were 
prepared and enterococci (deep red coloured colonies) were counted. Brilliance E. coli / coliform selective 
agar (CM1046, Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 24 hours at 
36 +/- 1 °C. Dilutions from 10-2 to 10-7 were made and E. coli (purple colonies) were counted. Tergitol 7 agar 
(CM0793, Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 24 hours at 36 
+/- 1 °C.  Dilutions from 10-2 to 10-7 were prepared and coliforms (any color) were counted. Baird Parker agar 
base (CM0275, Oxoid, Basingstoke, United Kingdom) with added 50 ml of Egg Yolk Tellurite Emulsion 
(SR0054, Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 48 hours at 36 
+/- 1 °C. Dilutions from 10-2 to 10-7 were made and Staphylococcus aureus (black, shiny colonies with white 
and clear zones) were counted. Anaerobe basal agar (CM0972, Oxoid, Basingstoke, United Kingdom) was 
pre-reduced and incubated under anaerobic conditions for 48 hours at 36 +/- 1 °C. Dilutions from 10-2 to 10-7 
were prepared and total cell count was measured. Each colony was checked for aerobic growth and ignored if 
so. Dichloran Rose-Bengal Chloramphenicol Agar (DRBC agar) (CM0727, Oxoid, Basingstoke, United 
Kingdom) was incubated under aerobic conditions for 48 hours at 36 +/- 1 °C. Dilutions from 10-1 to 10-2 were 
made and total yeast cell count was measured. Wilkins-Chalgren anaerobe agar (Code: CM0619, Oxoid, 
Basingstoke, United Kingdom) with added 1 vial of G-N Anaerobe Supplement (SR0108) and 25 ml 
defibrinated blood (SR0050/SR0051, both Oxoid, Basingstoke, United Kingdom) was pre-reduced and 
incubated under anaerobic conditions for 48 hours at 36 +/- 1 °C.  Dilutions from 10-3 to 10-8 were made and 
Bacteroides spp. (grey/white colonies partially mucoid and with tattered edges) were counted. Each colony 
was checked for aerobic growth and ignored if so. MRS agar (CM0361, Oxoid, Basingstoke, United Kingdom) 
with added 1 vial of polymyxin B supplement (SR0099, Oxoid, Basingstoke, United Kingdom) was pre-
reduced and incubated under anaerobic conditions for 48 hours at 36 +/- 1 °C. Dilutions from 10-3 to 10-8 were 
prepared and lactobacilli (pale straw coloured colonies) were measured. MRS-X agar (see MRS agar added 
0.25 g L-cysteine hydrochloride monohydrate, 1 g Lithium chloride and 1.5 g Sodium propionate dissolved in 
500 ml deionised water) was pre-reduced and incubated under anaerobic conditions for 48 hours at 36 +/- 1 
°C. Dilutions from 10-3 to 10-8 were made and checked for bifidobacteria (small, shiny colonies). Alcohol shock 
anaerobe basal agar was prepared as follows: 1 ml of the 1 g faeces diluted in 9 ml maximum recovery diluent 
with glycerol was mixed with 1 ml ethanol (≥98%, Sigma Aldrich, St. Louis, Missouri, USA) and rolled for 
30 min. Conditions were similar to anaerobe basal agar. Dilutions from 10-1 to 10-4 were made and total cell 
count was measured. Each colony was checked for aerobic growth and ignored if so. 
Stability of the faecal microbiota over time 
The function Adonis [Anderson, 2001] implemented in the Vegan package was used to test the variations 
between-samples of the microbial communities (calculated using the weighted Unifrac distance) over 
timepoints and among cages, via a permutational analysis of variance or non-parametric MANOVA. The linear 
predictors and response matrix were as following:  �௜௝௞ = � + �௜ + �௝ + ሺ� ∗ �ሻ௜௝ + �௞  + ሺ� ∗ �ሻ௞௜  +  ሺ� ∗ �ሻ௞௝  +  �௜௝௞ 
whereas:  �௜௝௞ is the weighted Unifrac matrix for treatment i, time j and cage k, 
µ  is the overall mean; �௜ is the effect of the ith time which was set as a class (T0, T1…T4); �௝ is the type of jth immunization which is represented by either TSHR or βgal;  �௞ is the effect of kth cage which is expressed as a class (C1, C2…C5); ሺ��ሻ௜௝   ሺ��ሻ௞௜ and ሺ��ሻ௞௝ represent factorial interactions between time, immunizarions and cage; 
 �௜௝௞ is the vector of the residual effects.  
A pairwise interaction within immunizations, cages and timepoints has been assessed using a built-in pairwise 
PERMANOVA script in R.  
 
 
 
 
 
Comparison Genus  mean rel. freq. (%) std. dev. (%)
Acetitomaculum 0.085566836 0.067504249
Bacteroides 1.52043332 0.853337957
Fusibacter 0.039939699 0.038703067
Genus_low 1.075302786 0.24891733
Lachnobacterium 0.316582459 0.238402725
Parabacteroides 0.031372369 0.045019329
Parasporobacterium 0.330871338 0.157904043
Peptococcus 0.085578215 0.075492454
Flavonifractor 0.128351482 0.066581061
Lactobacillus 18.59136704 13.88312945
Thiofaba 0.034233564 0.033267177
Acetitomaculum 0.2852081 0.129133521
Alloprevotella 0.156809908 0.287892738
Caminicella 0.053459424 0.052246474
Flavonifractor 0.16040369 0.081786875
TSHR vs . Bgal
TSHR vs . untreated
Bgal vs . untreated
mean rel. freq. (%)  std. dev. (%) difference between means P  value
0.2852081 0.129133521 -0.199641264 0.004050551
3.429600304 2.05523723 -1.909166984 0.046774268
0.007129617 0.012348858 0.032810082 0.035281823
1.372480403 0.263024859 -0.297177617 0.036977948
0.620236086 0.303623692 -0.303653627 0.048649574
0.07842986 0.034197543 -0.047057491 0.030341303
0.13901992 0.13777991 0.191851418 0.019845227
0.367221557 0.300765541 -0.281643342 0.043112267
0.04267177 0.048485122 0.085679711 0.016159478
5.048233808 3.731541414 13.54313324 0.018575293
0.004748338 0.010617607 0.029485226 0.031091947
0.07120383 0.056310395 0.21400427 0.002863369
1.344091904 0.872651646 -1.187281996 0.027430733
0 0 0.053459424 0.030322651
0.04267177 0.048485122 0.11773192 0.009190405
Timepoint Genera logFC (Bgal vs. TSHR) P  value
Guggenheimella -1.593418277 0.002971821
Peptococcus -2.61417971 0.019466113
Lactobacillus 1.343235012 0.024577578
Robinsoniella -3.065507327 0.001215322
Clostridium_IV -2.723185741 0.003591556
Butyrivibrio -2.293363835 0.006648556
Mucispirillum -2.774289292 0.013376972
Prevotella -8.903507981 0.016336149
Acetitomaculum -2.115372411 0.017863629
Anaerovorax -1.790900672 0.017890993
Lachnospiracea incertae sedis -1.516884723 0.023599357
Faecalibacterium -3.087910293 0.026495936
Intestinimonas -1.217734963 0.040317375
Lachnobacterium -1.347969782 0.044862787
Parasporobacterium 2.640927285 0.007515424
Parabacteroides -1.46702779 0.015591291
Lactobacillus 1.295658361 0.029238586
Galenea -3.574369446 0.04585986
Barnesiella -0.970464856 0.049220424
Papillibacter -2.487132887 0.000599142
Butyrivibrio 2.602585108 0.002932094
Marvinbryantia 1.871309072 0.004923226
Butyricimonas -1.491880466 0.022585778
Ruminococcus -2.242503921 0.030662741
Lachnobacterium -1.725906219 0.006700259
Acetitomaculum -1.868432268 0.020236501
Parasporobacterium 2.233031643 0.02213694
Coprobacter 0.772319802 0.022428431
Clostridium IV -1.533580692 0.03270514
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